pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$LENZLENZ Therapeutics, Inc.

$LENZ
Solana Beach, CA, USupdated 21d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Marketed: 1
1Marketed
Marketed
aceclidine
Presbyopia

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3Phase 3 Safety Study for the Treatment of Presbyopia Subjectscompletedn=362
  • phase1Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopiacompletedn=30

Insider activity

source: SEC Form 4

open-market buys + sells

  • Mar 27, 26BUYSchimmelpennink Evert B.· President, CEO and Secretary28,089 sh @ $8.95$251K↗
  • Mar 27, 26BUYChevallard Daniel R.· Chief Financial Officer7,500 sh @ $8.57$64K↗
  • Mar 27, 26BUYGeorge Jeffrey P.· director5,592 sh @ $8.92$50K↗
🐶 Hiring Signal
No open roles indexed yet — view LENZ Therapeutics, Inc. jobs →

News

  • Migraine biotech Vedana Therapeutics makes its debut with $46M Series A
    Vedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines entirely. Available treatments for…
    endpoints · 2mo ago
  • A new Westlake-backed biotech takes aim at migraines
    Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.
    biopharma_dive · 2mo ago
identifiers
ticker
$LENZ
SEC CIK
0001815776
country
US
source
sec_tickers
top tags
Ophthalmology1
mentioned in
2news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 17m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?